Merck-Eisai endometrial cancer therapy combo fails first-line treatment trial Ruchika Sharma9 Dec 2023 1:30 PM ISTRahway: Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line...
Setback: Merck-Eisai combination therapy fails in lung cancer studies Ruchika Sharma23 Sept 2023 2:21 PM ISTNew Jersy: Drugmakers Merck and Eisai said on Friday a combination of their cancer therapies did not prolong the lives of patients in two...
Merck, Eisai to shut down late stage study for combo cancer therapy Ruchika Sharma28 Aug 2023 12:31 PM ISTThe companies are testing the combination to treat a range of cancers, including those affecting the lungs and stomach.
Setback: Merck, Eisai to stop late-stage study of Keytruda plus Lenvima for metastatic melanoma Ruchika Sharma8 April 2023 2:01 PM ISTThey also said another late-stage trial for Keytruda and Lenvima did not meet its main goal of overall survival for treating a type of colorectal or...
Merck, Eisai get Japanese nod for cancer cocktail drug Keytruda, Lenvima Ruchika Sharma30 Dec 2021 12:22 PM ISTKenilworth: Merck, known as MSD outside the United States and Canada, and Eisai have announced that the Japanese Ministry of Health, Labour and...
